228612 - Chronic Obstructive Pulmonary Disease (Answered)

Liz Kendall
To ask the Secretary of State for Health, how much the Government has allocated to development of new drugs and treatments for chronic obstructive pulmonary disease each year from 2009-10 to 2014-15.

George Freeman

The following table shows estimated expenditure on research relating to the development of new drugs and treatments for chronic obstructive pulmonary disease (COPD) by Research Councils, Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.

£ million

2009/10

2010/11

2011/12

2012/13

2013/14

2014/15

Biotechnology and Biological Sciences Research Council (BBSRC)

0.0

0.1

0.1

0.1

0.0

0.0

Medical Research Council (MRC)

3.8

2.6

2.4

2.9

2.1

n/a

Innovate UK

0.0

0.0

0.3

1.3

1.4

0.6

NIHR

0.9

0.8

0.9

1.9

2.6

2.5

Total

4.7

3.5

3.7

6.2

6.1

n/a

Notes:

1. The BBSRC funds world class bioscience and biotechnology that underpins health research funded by others, but does not fund research directly relating to understanding/treating specific diseases. The underpinning health research that the BBSRC supports seeks to provide a better understanding of what makes a healthy biological system, and the key moderators of this health (both positive and negative), and also informs strategies to help maintain resilient health across the life-course and reduce the risk of emergence of diseases typically associated with age-related health decline. In the context of COPD, the BBSRC funds a small amount of directly underpinning biotechnology work on the development of new lung tissue models.

2. The MRC supports investigator-led research in response to proposals from the academic community and does not normally allocate funds to particular topics. High quality applications for support are welcomed into any aspect of human health and are judged in open competition with other demands on funding. Awards are made according to their scientific quality and importance to human health. The MRC also provides long term funding through our own research Units, often in partnership with Universities. In addition to research directly relating to the development of new drugs and treatments for COPD the MRC also supports a broader portfolio of research on COPD and other respiratory conditions which aims to advance our understanding and inform new treatments.

3. The Science and Technology Facilities Council (STFC) has not funded any research into the development of new drugs and treatments for COPD. STFC’s Central Laser Facility and the Diamond Light Source have provided access for research by other organisations.

4. Total spend by the NIHR on research relating to the development of new drugs and treatments for COPD is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these topics cannot be disaggregated from total CRN expenditure.